AZN - Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

2024-02-24 20:53:46 ET

Summary

• Topline 36-week data from the phase 2 ALPACAR-360 study using its drug zerlasiran for patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease, expected in Q1 2024.
• There are four other data readouts/presentations expected in 2024, which relate to the use of zerlasiran for the treatment of patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease.
• The global cardiovascular disease drugs' market size is expected to reach $186.1 billion by 2032; Targeting lipoprotein[a] for cardiovascular disease is an unmet need.
• Another candidate in its pipeline would be divesiran, which is being advanced in the phase 1 SANRECO-PV study treating patients with polycythemia vera; Results from this study are expected to be released in mid-2024.

Silence Therapeutics ( SLN ) is gearing up to report topline 36-week data from its phase 2 ALPACAR-360 study, which is using its drug zerlasiran [formerly known as SLN360] for the treatment of patients with high lipoprotein[a] and stable atherosclerotic cardiovascular disease [ASCVD]. It is expected to release such data in Q1 of 2024 and positive data here would reconfirm prior findings from a phase 1 study, whereby positive data was achieved. The hope is that positive data is achieved with respect to this phase 2 ALPACAR-360 study. Besides positive data causing the stock price to trade higher, it would also allow for several other catalysts to come about that could provide additional upside. Matter of fact, should results using zerlasiran for this ASCVD patient population be good, then it would mean another four catalysts on the way....

For further details see: